LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study-Reference-Cited by-同舟云学术

LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Published:2023-10 Issue: Volume:34 Page:S1279-S1280
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lorusso D.,Xiang Y.,Hasegawa K.,Scambia G.,Leiva Galves M.H.,Ramos Elias P.,Acevedo A.,Vizkeleti J.,Gomes A.J.P.D.S.,Contreras Mejia F.,Reiss A.,Ayhan A.,Lee J-Y.,Saevets V.,Zagouri F.,Li K.,Ussui Yamada K.,Toker S.,Pignata S.,Duska L.R.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future;Expert Opinion on Drug Metabolism & Toxicology;2024-09-09

2. Inhibition of ADAM17 increases the cytotoxic effect of cisplatin in cervical spheroids and organoids;Frontiers in Oncology;2024-09-02

3. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group;International Journal of Gynecologic Cancer;2024-06-30

4. Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy;British Journal of Radiology;2024-06-04

5. MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy;Radiotherapy and Oncology;2024-06